Physician profile
Michael L Murphy
NPI 1205893880
$521.56
in general payments reported to CMS, 2019-2025
10 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2023: $160 · 2024: $149 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $186.11 | 2021-2024 | Clareon |
| Horizon Therapeutics Plc | $124.98 | 2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $36.66 | 2023-2025 | Syfovre |
| Abbvie INC. | $30.49 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $29.33 | 2024 | Eylea Hd |
| Genentech USA, INC. | $28.00 | 2025 | Vabysmo |
| Oyster Point Pharma, INC. | $22.60 | 2024 | Ryzumvi, Tyrvaya |
| Amgen INC. | $21.67 | 2024 | Tepezza |
| Acclarent, INC | $21.24 | 2023 | Relieva Spinplus |
| Dompe US, INC. | $20.48 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.